Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Capricor Therapeutics, Inc. (CAPR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8900-0.1700 (-5.56%)
At close: 04:00PM EST
3.0300 +0.14 (+4.84%)
After hours: 05:03PM EST
Advertisement
Sign in to post a message.
  • S
    Safet
    Great price for investment. Buy and hold.
    Bullish
  • S
    Safet
    At the moment, the largest volume is since Oct 12, 2021.
  • J
    Jerry
    ok loaded big time let's go
    Bullish
  • j
    jerzy
    PARTNERSHIP COMING BEFORE CHRISTMAS. LINDA CAN'T REVEIL ANY NEWS DURING NEGOTIATIONS. BE PATIENT IS COMING.
  • P
    P
    Royalty Pharma is a partnership machine. It partners with companies to fund late-stage studies and new product launches in exchange for future royalties. The biotech company also acquires existing royalties from the original companies. Royalty counts AbbVie (ABBV), Johnson & Johnson (JNJ), Biogen (BIIB) and others among its partners.
  • j
    jerzy
    In a frame 1-2 years this will have an evaluation comparable to SRPT around 7 billion dollars. Only most patient will make huge money here.
  • g
    gayle siebern
    This has nothing to do with Delta, in fact people have really hard time placing in on the tree — it is so far removed from anything else that it just sits on a very long branch of its own.

    It also shows a lot of genetic diversity within the ~25 sequences that are available so far, which is a mystery on its own. Usually that suggests a lot of circulation out of sight somewhere where they don’t sequence a lot. Congo-Brazzaville does fit the description, but it is still interesting that it only came out now. My guess is it was festering somewhere in the countryside there, then it made its way to Brazzaville, which is probably the only place in Congo where they sequence anything, and from there it got to France. And from France it got to California, the UK, Italy, Switzerland, and now the Netherlands too (there was another sequence posted yesterday).

    Africa is just a black hole in terms of surveillance.

    They do an excellent job in South Africa relative to the other countries, to the extent that we even know that for some mysterious reason, the region about Port Elizabeth is specifically the one that produces the most nasty variants — both B.1.351 and B.1.638 all seem to trace to there, not entirely sure about C.1.2 — but even then it is nowhere near the level of the UK, for understandable reasons. Which is why C.1.2 and B.1.638 show up all of a sudden and you already see a complex mix of subvariants indicating long cryptic spread and diversification that nobody noticed.

    But the rest of the continent is just largely a blank.

    The Tanzanian A.30 variant was only spotted in South Africa in travelers.

    B.1.620 seems to have originated in the Cameroon/CAR/Congo-Brazzaville neighborhood (most likely southeastern Cameroon), but was only identified in Lithuania of all places.

    Hello Linda.

    https://www.nakedcapitalism.com/2021/11/new-radically-different-covid-variant-getting-footholds-now-as-media-and-officials-remain-complacent.html
  • g
    gayle siebern
    “We remain committed to our goal of developing and delivering AT-527 as an oral antiviral that will address treatment needs as Covid-19 continues to evolve,” Atea CEO Jean-Pierre Sommadossi said in a statement.

    Atea’s drug works similarly to Merck’s and was widely expected to succeed in clinical development. The problem might have been trial design. While Merck deliberately excluded patients who had been vaccinated for Covid-19, Atea did not, which might have skewed the results, according to the company. Merck also recruited only patients who had at least one risk factor for severe Covid-19, such as obesity or heart disease, while Atea required only a positive test and mild symptoms.

    The news is a bitter disappointment for Atea, which has spent the past 18 months touting the potential of AT-527, developed as a treatment for hepatitis C, to change the course of the Covid-19 pandemic. The company, which commanded a market value of about $3.4 billion as of Monday, fell 70% in premarket trading on Tuesday.

    Merck, partnered with Ridgeback Biotherapeutics, is seeking an emergency use authorization for its Covid-19 antiviral and will make its case to a panel of Food and Drug Administration advisers on Nov. 30. Results for another potential oral Covid-19 treatment, from Pfizer, are expected by the end of the year.
  • P
    P
    buy out at 20. ? leaving to much on the table for my liking.
  • R
    RenaissanceM
    Read the conference call transcript again, and it reassured my confidence the science is solid, and their are catalysts on the very near horizon. An NDA filing in the 4th quarter, achievement of full patient enrollment, and ongoing observation of phase 2 participants who continue to get treated. Also was encouraged by patient reports of improvement and just feeling better. Linda stressed the structure of phase three is designed to ensure fda approval. It is clear she is determined that there will be no way the phase 3 design will be flawed and no way the expected data will not support FDA approval and achieve endpoints. She appears focused and hellbent on success of FDA approval to get this drug to help the many patients in need. The stock is cheap.. she emphasized non diluting financing, which should put many investors at ease.
  • e
    ed
    Wainwright raises Target from 9 to 14!
  • j
    jerzy
    SRPT just sold 500 million in stock. Anyone knows why ? I'll tell you why, eater is partial or full buy out of capr. We'll find out soon. Longs and bulls sleep well .
  • R
    RenaissanceM
    Confusion. It is assumed meeting endpoints is proof of efficacy of improvement from baseline. that is in context. If disease progression slowed that is not a reversal, but it is proof the drug has a positive effect. Like Alzheimers it is a big deal if you can slow the progression of the disease
    That does not jive with a statement that disease progression slowed by 71 per cent over one year. That goes with the other endpoints as well, however it appears to say ejection fraction was a reversal or was that too only an improvement from placebo and actually lessened, but not as much as the placebo group. I think the one video shows marked improvement. I think the company needs to clarify some of this
    Apparently the superior results were compared to placebo, people got worse, but people on placebo got much more worse.
  • P
    Peter
    While the results are encouraging a 20 patients study is not a impressive number but phase 2 trials are partially about safety the efficacy numbers will be more clear after a phase 3 trial. It also appears that the patients selected for this study were in pretty bad shape and failed conventional treatment. I bought 4,000 shares even though we may not see any phase 3 data for year. I equally like the company for its covid antiviral product. Ivermectin has proven to be a effective early treatment option and while every major drug company is working on a antiviral project CAPR is unique because of thier size and experience in the space. The second has pulled back to the $5.10 range. News on these drugs will increase as Merk, Pfizer, J&j all are coming out with antivirals. Merk's trial is going well but you may not here any data for another 45 days but the government already placed a order.
  • L
    Leo
    Capricor Stock Is Moving Higher As Duchenne Dystrophy Cell Therapy Slows Disease Progression By 71%.....................it means 71% down
  • j
    jerzy
    Ok.everyone this is ready to run.
  • J
    Jerry
    Short interest increased from 600k shares to 1.1 million since p2 data.
    Bullish
  • T
    Timmy
    $CASI conversation
    CALA - with $150M market cap is next biotech to go huge this year ; well funded and targeting multi billion dollar markets 🔥💎 2 data readouts ahead 💥

    CALA ; Q4 play with catalysts ahead;

    ✅2 significant data catalysts coming up in Q4

    ✅$80M cash / no debt / low cash burn

    (Analysts are on CALA for Keapsake data giving >100% upside potential on interim study results Q4) $25B market for NSCLC

    (Also new Phase 1b interim data to be presented at North American Cystic Fibrosis conference Nov 2-5) $8B market for CB

    ✅Licensed their CD73 with Antengene earlier this year - Calithera will receive an upfront payment and potential development, regulatory and sales milestones of up to $255.0 million.

    CRVS ran 277% earlier this month after AstraZeneca CD73 Success, as it’s the only baby bio with CD73 that isn’t partnered...

    $SURF $ORTX $ALRN $CAPR
    Bullish
  • j
    jerzy
    Everyone remember this is bio company with very strong pipeline, and the outlook and price can change over night. I would be very careful to underestimate this company. MC is at this point irrelevant and we'll reflect soon what the real worth of this company is.
Advertisement
Advertisement